-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is reported that China's original new drug for the treatment of Alzheimer's disease, Mannite Sodium Capsules (trade name: Nine Phase One®) has been included in the medical insurance for more than half a month.
There are currently more than 10 million Alzheimer's disease (Alzheimer's disease, also known as Alzheimer's disease) patients in China, and this will accelerate the growth of the population with the aging process, causing extremely heavy social and economic burdens
Jiu Phase One® is a new type of AD treatment drug.
Since October 2019, Geng Meiyu’s team published research results related to the mechanism of action of GV-971 (the code used in the study period of Nine Phase One®) in the form of a cover article on "Cell Research".
According to the "Medical Insurance Catalog (2021)" announced on the 3rd of this month, Nine Phase One® entered the list of 74 new medical insurance drugs.